End-stage renal disease is 5-fold more likely to develop in patients with 3 or more infection-related hospitalizations versus none.

The primary outcome was reduction in proteinuria, as measured by protein-to-creatinine (P:C) ratio in a 12-hour urine collection, at 24 weeks compared with baseline.

The development of this scale, once further validated, will give clinicians the ability to verify lupus nephritis activity without the need for an invasive kidney biopsy.

Among the findings, researchers found no association between mixed or pure histopathologic features of LN at presentation and rates of complete or partial remission.

Researchers find an increased risk of death among patients.

Athcar gel may be a treatment option for patients with treatment-resistant nephrotic syndrome.

New study also provides evidence that an early proteinuria decrease is a strong predictor of good long-term outcome.

The risk of end-stage renal disease in patients with systemic lupus erythematosus may even be declining, but outcomes differ by race.

The condition appears to be associated with high hospitalization and death rates, researchers reported.

A plant-based compound could provide a new treatment for lupus nephritis with fewer side effects.

Large study looked at matched pairs of lupus patients with renal disease starting dialysis with hemodialysis or peritoneal dialysis.

A 50% or greater reduction in proteinuria after six months of treatment for severe lupus nephritis predicted better 15-year renal survival.

Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.